Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/13993003.00388-2016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lumbar Spine Injuries in Recreational Athletes: A Review.
J Am Acad Orthop Surg
January 2025
From the Department of Orthopaedic Surgery (Dr. Hsu), Northwestern University Feinberg School of Medicine, Chicago, IL, the Department of Orthopaedic Surgery, Atrium Health (Dr. Turk), Carolinas Medical Center, Charlotte, NC, and the OrthoCarolina Spine Center (Dr. Spector), Charlotte, NC.
Back pain that is associated with lumbar spine pathology is a growing issue in the athlete population. As an aging population continues to remain active, it is essential for primary care physicians, general orthopaedic surgeons, and spine surgeons alike to understand the nuances of diagnosis and management in the recreational athlete population. This is a unique population due to the increased importance placed on returning to high levels of activity, but, by definition, they enjoy less resources and financial incentive to optimize their rehabilitation and return to sport compared with professional athletes.
View Article and Find Full Text PDFRecent advances in immunotherapy for cervical cancer.
Int J Clin Oncol
January 2025
Department of Gynecologic Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka-shi, Saitama, 350-1298, Japan.
Cervical cancer is the third most common malignant tumor in women worldwide in terms of both incidence and mortality. The field of cervical cancer treatment is rapidly evolving, and various combination therapies are being explored to enhance the efficacy of immune checkpoint inhibitors (ICI) and provide new treatment options for patients at different disease stages. Clinical trials involving immune checkpoint inhibitors are now being conducted following a phase 3 trial with cemiplimab, an ICI, which demonstrated a significant improvement in prognosis in advanced or metastatic cervical cancer patients.
View Article and Find Full Text PDFEffects of denosumab and zoledronic acid on postmenopausal osteoporosis, bone density, and fat-free mass.
Arch Osteoporos
January 2025
Division of Endocrinology & Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Unlabelled: This study compared denosumab and zoledronic acid for treating osteoporosis in drug-naïve postmenopausal Korean women. Over 3 years, both drugs significantly increased bone mineral density. However, denosumab also improved fat-free mass, suggesting it may be a better initial treatment for osteoporosis with low muscle mass, assuming all other conditions remain constant.
View Article and Find Full Text PDFTargets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements.
Curr Treat Options Oncol
January 2025
Tianjin Medical University General Hospital, 154 Anshan Road, Tianjin, 300052, Heping District, China.
According to the guidelines, the primary treatment for multiple myeloma is still based on drugs such as carfilzomib, lenalidomide, or daratumumab. However, patients with relapsed/refractory multiple myeloma (RRMM) may be insensitive or develop resistance to the above therapeutic medications. Thus, formulating standardized and rational treatment regimens for such patients remains an area for consideration.
View Article and Find Full Text PDFBarriers and facilitators to treat-to-target in axial spondyloarthritis in clinical practice: a mixed methods study.
Rheumatol Int
January 2025
Department of Rheumatology, Maastricht University Medical Centre+, P.O. Box 5800, Maastricht, 6202 AZ, The Netherlands.
This study aimed to explore the perceptions of patients and rheumatologists about a treat-to-target (T2T) strategy in axial spondyloarthritis (axSpA) and identify the barriers and facilitators to its implementation in clinical practice. A mixed methods design was applied. Patients with axSpA who visited the outpatient clinic with active disease (AxSpA Disease Activity Score [ASDAS] ≥ 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!